PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
0.00 - 0.01
0.00 - 0.02
289 / 496.9K (Avg.)
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
187.83%
Positive revenue growth while XRF.AX is negative. John Neff might see a notable competitive edge here.
141.82%
Positive gross profit growth while XRF.AX is negative. John Neff would see a clear operational edge over the competitor.
1131.48%
Positive EBIT growth while XRF.AX is negative. John Neff might see a substantial edge in operational management.
1131.48%
Positive operating income growth while XRF.AX is negative. John Neff might view this as a competitive edge in operations.
682.71%
Net income growth above 1.5x XRF.AX's 13.78%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
500.00%
EPS growth above 1.5x XRF.AX's 12.54%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
500.00%
Diluted EPS growth above 1.5x XRF.AX's 12.54%. David Dodd would see if there's a robust moat protecting these shareholder gains.
-3.85%
Share reduction while XRF.AX is at 1.21%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-2.97%
Reduced diluted shares while XRF.AX is at 1.24%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
-1723.26%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-4204.46%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
-31.83%
Negative 10Y revenue/share CAGR while XRF.AX stands at 151.40%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
221.27%
5Y revenue/share CAGR above 1.5x XRF.AX's 74.52%. David Dodd would look for consistent product or market expansions fueling outperformance.
105.69%
3Y revenue/share CAGR above 1.5x XRF.AX's 49.22%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
-277.17%
Negative 10Y OCF/share CAGR while XRF.AX stands at 132.15%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-424.53%
Negative 5Y OCF/share CAGR while XRF.AX is at 1139.05%. Joel Greenblatt would question the firm’s operational model or cost structure.
-668.10%
Negative 3Y OCF/share CAGR while XRF.AX stands at 144.47%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
408.00%
Net income/share CAGR above 1.5x XRF.AX's 198.79% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
500.00%
5Y net income/share CAGR above 1.5x XRF.AX's 195.12%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
60.00%
3Y net income/share CAGR 75-90% of XRF.AX's 72.97%. Bill Ackman might push for an operational plan to match or beat the competitor’s short-term growth.
No Data
No Data available this quarter, please select a different quarter.
1831.22%
5Y equity/share CAGR above 1.5x XRF.AX's 52.04%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
116.58%
3Y equity/share CAGR above 1.5x XRF.AX's 30.57%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
219.76%
Our AR growth while XRF.AX is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
-7.99%
Inventory is declining while XRF.AX stands at 4.59%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
28.58%
Positive asset growth while XRF.AX is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
27.93%
Positive BV/share change while XRF.AX is negative. John Neff sees a clear edge over a competitor losing equity.
51.86%
Debt growth far above XRF.AX's 35.08%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
-100.00%
Our R&D shrinks while XRF.AX invests at 0.00%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
15.25%
We expand SG&A while XRF.AX cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.